Articles tagged with 'Research & Innovation' | Bayer

Newsroom Bayer (Research & Innovation)

2023
March
24,
2023
| 14:59 PM Europe/Amsterdam
Late-stage development programs with significant potential to drive long-term growth / New R&D strategy and operating model sharpening innovation focus and strengthening early development pipeline in oncology, cardiovascular, neurology & rare disease...
Read more
March
23,
2023
| 13:59 PM Europe/Amsterdam
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline / Fifth major cl...
Read more
March
20,
2023
| 07:59 AM Europe/Amsterdam
Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer / Additional indication based on data from the pivotal Phase III ARASENS trial ...
Read more
March
14,
2023
| 12:59 PM Europe/Amsterdam
Ready-to-use AgPowered Services from Bayer running on the new Microsoft Azure Data Manager for Agriculture / Readymade capabilities and robust digital infrastructure allow innovators to focus on differentiated value / Companies, farmers and consumers...
Read more
March
14,
2023
| 12:45 PM Europe/Amsterdam
Rune Labs’ StriveStudy platform and Emerald Innovations’ Emerald wireless monitoring sensor will passively capture data on Parkinson’s disease impact on function of fifty study participants in BlueRock’s global non-interventional clinical study.  / C...
Read more
March
06,
2023
| 09:59 AM Europe/Amsterdam
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chro...
Read more
March
01,
2023
| 11:59 AM Europe/Amsterdam
European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III ARASENS trial data...
Read more
March
01,
2023
| 07:59 AM Europe/Amsterdam
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PUL...
Read more
February
27,
2023
| 07:59 AM Europe/Amsterdam
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer / New approval based on data from the pivotal Phase III ARASENS trial 
Read more
February
22,
2023
| 08:29 AM Europe/Amsterdam
Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI / Further research explores potential of AI and digital advances in medical imaging 
Read more
February
16,
2023
| 19:59 PM Europe/Amsterdam
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various t...
Read more
February
10,
2023
| 09:59 AM Europe/Amsterdam
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (...
Read more
February
08,
2023
| 08:59 AM Europe/Amsterdam
Partnering with players along the food value chain is key to tackle challenges of food security and climate change / Bayer makes substantial progress in accelerating development of biologicals through collaborations with Ginkgo Bioworks, Kimitec and ...
Read more
February
06,
2023
| 10:59 AM Europe/Amsterdam
Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON / In both trials, aflibercept 8 mg demonstrated unprecedented...
Read more
February
02,
2023
| 08:59 AM Europe/Amsterdam
Both companies enter into a global strategic partnership for Biologicals discovery and commercialization, that includes crop protection and biostimulant products based on molecules derived from natural sources / Kimitec becomes a new strategic partne...
Read more
January
31,
2023
| 14:58 PM Europe/Amsterdam
The Professor at the Institute of Organic Chemistry at the University of Münster receives the award in recognition of his groundbreaking work / Professor Antje Boetius, Director of the Alfred Wegener Institute (AWI) in Bremerhaven, is presented with ...
Read more
January
27,
2023
| 12:59 PM Europe/Amsterdam
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel alone, with sim...
Read more
January
23,
2023
| 08:29 AM Europe/Amsterdam
Ultravist™-300, -370 receives green light for indication extension for use in contrast-enhanced mammography (CEM) in a European Workshare Procedure  / CEM is emerging modality combining digital mammography with the administration of a contrast agent ...
Read more
2022
December
20,
2022
| 19:09 PM Europe/Amsterdam
Research Triangle Park, N.C. (December 20, 2022) - Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary of Bayer AG, today announced that the FDA’s approval of a new adeno-associated virus (AAV) gene therap...
Read more
December
06,
2022
| 12:59 PM Europe/Amsterdam
The Bayer Science Collaboration Explorer makes contract-based scientific collaborations with universities, public research institutions and individuals publicly available in the U.S.  / Aim of the database is to foster public trust in science by show...
Read more
November
22,
2022
| 14:00 PM Europe/Amsterdam
New clinical data for the development compound gadoquatrane, a novel MRI contrast agent, presented at RSNA 2022 / Three new partnerships, AI app accelerator program and pipeline updates to be featured / Collaboration agreements signed to expand offer...
Read more
November
11,
2022
| 14:52 PM Europe/Amsterdam
Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT / Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness / Bayer will apply for a patent term extension for the pat...
Read more
November
09,
2022
| 13:30 PM Europe/Amsterdam
San Diego – November 9, 2022 – Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune diso...
Read more
November
05,
2022
| 06:59 AM Europe/Amsterdam
Aflibercept 8 mg maintained 16-week dosing intervals in up to 89% of patients with as few as 5 injections until week 48 / Aflibercept 8 mg demonstrated non-inferior vision gains to Eylea® (aflibercept 2 mg) with 83% of patients with neovascular (wet)...
Read more
October
26,
2022
| 12:00 PM Europe/Amsterdam
FIDELITY: Late-breaking data from pooled, post-hoc analysis will provide new insights into the efficacy and safety of Kerendia in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) who have sustained an acute change in estimated glo...
Read more
October
26,
2022
| 09:00 AM Europe/Amsterdam
The newest LifeHub in the Bayer network will connect the company more closely to the German innovation ecosystem of scientists, researchers, decision makers, and entrepreneurs / Focus lies on dialogue and innovation through open approaches that contr...
Read more
October
25,
2022
| 08:28 AM Europe/Amsterdam
The REALISE study explored symptom burden and impact of menopause symptoms in women across multiple countries, and the views of their treating physicians.  / This study confirmed vasomotor symptoms (VMS) are considered the most common and distressing...
Read more
October
20,
2022
| 08:29 AM Europe/Amsterdam
Bayer, together with the Bill & Melinda Gates Foundation, are jointly funding pre-clinical research in the area of novel non-hormonal contraception / This collaboration with the Bill & Melinda Gates Foundation will contribute to expanding access to c...
Read more
October
18,
2022
| 12:59 PM Europe/Amsterdam
Ginkgo Bioworks becomes a multi-year strategic partner with Bayer to develop biological solutions in areas such as nitrogen optimization, carbon sequestration, and next generation crop protection / Open Innovation Sourcing is expected to accelerate B...
Read more
October
17,
2022
| 09:00 AM Europe/Amsterdam
Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients  / Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vaso...
Read more